Novavax Quarterly Cash Flow Statement
NASDAQ: NVAXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Novavax free cash flow
In the quarter ended Jun 30, 2026, Novavax generated -$72.8 million of operating cash flow and spent $588,000 on capital expenditures. That left free cash flow of -$73.4 million, a free-cash-flow margin of -129.4% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Novavax cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -53.39M | -9.49M | 17.53M | -202.38M | 106.51M | 518.65M | -81.03M | -121.30M | 162.38M | -147.55M | -178.39M | -130.78M |
| Net Income growth (YoY) | -150.12% | -101.83% | — | — | -34.41% | — | — | — | +179.93% | — | — | — |
| Depreciation & Amortization | 3.06M | 3.06M | 5.13M | 6.58M | 7.56M | 8.34M | 12.52M | 12.70M | 11.13M | 12.15M | 10.79M | 11.32M |
| Stock-Based Compensation | 8.09M | 7.72M | 7.97M | 8.55M | 9.21M | 10.29M | 10.45M | 12.05M | 14.10M | 11.56M | 15.66M | 20.76M |
| Change in Working Capital | -33.25M | -25.01M | -73.70M | 165.93M | -240.33M | -739.60M | -41.74M | -15.34M | -1.95M | 36.81M | -49.59M | 262.86M |
| Operating Cash Flow | -72.81M | -32.42M | -39.48M | 107.80M | -127.46M | -185.50M | -173.16M | -144.81M | 314.27M | -83.56M | -176.78M | -39.66M |
| Capital Expenditures | -588.00K | -1.27M | -2.08M | -1.36M | -527.00K | -1.59M | -1.93M | -1.37M | -2.88M | -6.88M | -8.84M | -18.16M |
| Investing Cash Flow | 34.90M | -28.36M | 20.48M | -136.53M | 111.10M | -73.32M | 144.01M | 31.91M | -372.71M | -7.25M | -9.08M | -18.39M |
| Financing Cash Flow | 1.20M | 37.67M | -6.60M | 42.44M | -1.04M | -7.06M | -3.42M | -97.00K | 258.22M | 5.89M | 100.39M | 197.12M |
| Net Change in Cash | -36.88M | -23.13M | -27.30M | 14.38M | -9.50M | -266.81M | -43.30M | -106.97M | 199.62M | -87.87M | -82.55M | 148.42M |
| Free Cash Flow | -73.39M | -33.69M | -41.55M | 106.44M | -127.99M | -187.10M | -175.09M | -146.19M | 311.39M | -90.43M | -185.62M | -57.81M |
This table shows 12 quarterly periods of Novavax's cash flow statement, from Q2 2026 back to Q3 2023, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow NVAX's reporting calendar. What is a cash flow statement?